Nan Liu Enterprise Co., Ltd. (6504)

Overview

Cannasouth Limited operates in the burgeoning field of medicinal cannabis, with its primary operations centered around the cultivation and manufacturing of pharmaceutical-grade cannabis ingredients and medicinal products. This innovative enterprise is dedicated to the development of cannabinoid-based therapeutics aimed at improving health outcomes for both humans and animals. Positioned in Hamilton, New Zealand, Cannasouth stands as a pioneering entity in the realm of cannabis research and medical solution development, navigating the complex regulatory and scientific landscapes to provide next-generation health solutions.

Products and Services

• Cannabis Pharmaceutical Ingredients

  Specializes in the production of high-quality, pharmaceutical-grade cannabinoids, which serve as the foundational components for a range of medical treatments. These ingredients are rigorously developed and tested to meet stringent quality and safety standards, ensuring they are suitable for use in various therapeutic applications.

• Medicines Development

  Focuses on the formulation and creation of cannabinoid-based medicines designed to aid in treating a multitude of medical conditions. Leveraging cutting-edge science and technology, Cannasouth seeks to harness the therapeutic potential of cannabis to innovate and produce effective medical solutions.

• Cannabinoid Therapeutics for Animals

  Expands the benefits of cannabinoid research to the animal health sector, developing safe and effective treatments for a variety of conditions affecting domestic and farm animals. This line of research and product development illustrates the company's commitment to improving health outcomes across a broad spectrum of living beings.